search
Back to results

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Primary Purpose

B-cell Leukemia

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
CD19/CD20 Dual-CAR-T cells
Sponsored by
Hebei Yanda Ludaopei Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for B-cell Leukemia

Eligibility Criteria

1 Year - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Relapsed and refractory B-cell acute malignancies with:

    • Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%);
    • MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD ≥ 0.1% after HSCT;
    • Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD ≥ 0.1%;
  2. Patients must have evaluable evidence of disease, including minimal residual disease (MRD);
  3. Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant;
  4. Double positive expression of CD19 / CD20 in B cells;
  5. Ages 1 to 70 years, including boundary values;
  6. ECOG score 0-3 points;
  7. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside.
  8. Patients who voluntarily sign informed consent and are willing to comply with treatment plans.

Exclusion Criteria:

  1. patients with organ failure:

    • Heart: NYHA heart function grade IV;
    • Liver: Grade C that achieves Child-Turcotte liver function grading;
    • Kidney: kidney failure and uremia;
    • Lung: symptoms of respiratory failure;
    • Brain: a person with a disability;
  2. Active infections that are difficult to control;
  3. Human immunodeficiency virus (HIV) positive;
  4. Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min;
  5. GVHD ≥ 2 or anti-GVHD treatment;
  6. Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion;
  7. Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week;
  8. Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL);
  9. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
  10. pregnant or lactating women;
  11. The patient does not agree to use effective contraception during the treatment period and for the next 3 months;
  12. Patients who participate in other clinical studies at the same time;
  13. The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.

Sites / Locations

  • Hebei Yanda Ludaopei Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CD19/CD20 Dual-CAR-T cells

Arm Description

CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.

Outcomes

Primary Outcome Measures

Percentage of participants with adverse events.
Objective remission rate(ORR)
The percentage of participants who achieved complete remission (CR) and partial remission over all participants.

Secondary Outcome Measures

Relapse-Free Survival(RFS )
Overall-Survival(OS)
Persistence of CAR-T cells in vivo

Full Information

First Posted
February 6, 2020
Last Updated
March 6, 2022
Sponsor
Hebei Yanda Ludaopei Hospital
Collaborators
China Immunotech (Beijing) Biotechnology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04260945
Brief Title
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Official Title
CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
March 10, 2020 (Actual)
Primary Completion Date
October 10, 2021 (Actual)
Study Completion Date
February 10, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hebei Yanda Ludaopei Hospital
Collaborators
China Immunotech (Beijing) Biotechnology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.
Detailed Description
This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell leukemia. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell leukemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
B-cell Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CD19/CD20 Dual-CAR-T cells
Arm Type
Experimental
Arm Description
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Intervention Type
Biological
Intervention Name(s)
CD19/CD20 Dual-CAR-T cells
Intervention Description
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
Primary Outcome Measure Information:
Title
Percentage of participants with adverse events.
Time Frame
6 months
Title
Objective remission rate(ORR)
Description
The percentage of participants who achieved complete remission (CR) and partial remission over all participants.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Relapse-Free Survival(RFS )
Time Frame
6 months
Title
Overall-Survival(OS)
Time Frame
6 months
Title
Persistence of CAR-T cells in vivo
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Relapsed and refractory B-cell acute malignancies with: Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%); MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD ≥ 0.1% after HSCT; Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD ≥ 0.1%; Patients must have evaluable evidence of disease, including minimal residual disease (MRD); Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant; Double positive expression of CD19 / CD20 in B cells; Ages 1 to 70 years, including boundary values; ECOG score 0-3 points; Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside. Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: patients with organ failure: Heart: NYHA heart function grade IV; Liver: Grade C that achieves Child-Turcotte liver function grading; Kidney: kidney failure and uremia; Lung: symptoms of respiratory failure; Brain: a person with a disability; Active infections that are difficult to control; Human immunodeficiency virus (HIV) positive; Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min; GVHD ≥ 2 or anti-GVHD treatment; Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion; Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week; Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL); intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; pregnant or lactating women; The patient does not agree to use effective contraception during the treatment period and for the next 3 months; Patients who participate in other clinical studies at the same time; The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.
Facility Information:
Facility Name
Hebei Yanda Ludaopei Hospital
City
Sanhe
State/Province
Hebei
ZIP/Postal Code
065200
Country
China

12. IPD Sharing Statement

Learn more about this trial

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

We'll reach out to this number within 24 hrs